Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![3-Women-Authors]( "The Center For Breakthrough Medicines’ Newest Leaders Talk Advanced Therapy Development, Manufacturing")
The Center For Breakthrough Medicines’ Newest Leaders Talk Advanced Therapy Development, Manufacturing4/1/2021I had the opportunity to connect with four of The Center for Breakthrough Medicines' newest leaders about their respective roles, the future of manufacturing, and much more.
-
![SARs Covid globe iStock-1219889249.jpg]( "Inside Repertoire Immune Medicines’ T Cell Recognition Of SARS-CoV-2")
Inside Repertoire Immune Medicines’ T Cell Recognition Of SARS-CoV-24/1/2021Anthony Coyle, Ph.D., President, Research and Development at Repertoire Immune Medicines explains the company's DECODE platform and the role it played in the T cell recognition of SARS-CoV-2.
-
![iStock-1015942770-stem cells]( "Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-19")
Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-193/23/2021Tevogen Bio recently announced its partnership with BioCentriq, a New Jersey-based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.
-
![bobby gaspar]( "Orchard Therapeutics’ CEO One Year In, Part 2")
Orchard Therapeutics’ CEO One Year In, Part 23/16/2021In part one of my sit down with Dr. Bobby Gaspar, CEO of Orchard Therapeutics, I explained how he officially took over the reins on March 18, 2020. You’ll also want to listen in to our podcast with Dr. Gaspar for an update on the company’s pipeline progress gives way to an in-depth discussion on the process challenges his company faces in the production of hematopoietic stem cells to treat neurometabolic disorders, primary immune deficiencies, and blood disorders.
-
![bobby gaspar]( "Orchard Therapeutics’ CEO One Year In")
Orchard Therapeutics’ CEO One Year In3/12/2021Dr. Bobby Gaspar, CEO of Orchard Therapeutics, officially took over the reins on March 18, 2020. You read the date correctly — Gaspar became CEO at the very beginning of the COVID-19 pandemic. One year later, and despite the global pandemic, Orchard boasts its first commercial approval.
-
![Cell]( "Reducing the Manufacturing Costs of Allogeneic Cell Therapies")
Reducing the Manufacturing Costs of Allogeneic Cell Therapies3/9/2021On the heels of our second Cell & Gene Live event sponsored by Invetech, Can Innovation Drive Down Cell Therapy Manufacturing Costs?, here we focus on the strategies that can reduce the manufacturing costs of allogeneic cell therapies.
-
![Breast Cancer Cell]( "Immunitas Therapeutics On The Future Of Immuno-Oncology")
Immunitas Therapeutics On The Future Of Immuno-Oncology2/25/2021Immunitas Therapeutics' scientific Co-Founder Kai Wucherpfenning, M.D., Ph.D. explains the role robotic automation plays in immunology, the use of single-cell RNA sequencing in their study, as well as the future of immuno-oncology.
-
![Cost]( "Driving Down Costs of Autologous Cell Therapy Manufacturing")
Driving Down Costs of Autologous Cell Therapy Manufacturing2/19/2021In this article, we will focus on ways to drive down the cost of manufacturing autologous cell therapies as explained in the Cell & Gene Live event.
-
![DNA Gene Strand]( "Codiak Biosciences On The Promise Of Engineered Exosomes For Drug Delivery")
Codiak Biosciences On The Promise Of Engineered Exosomes For Drug Delivery2/18/2021Here's an inside look at Codiak BioSciences, which launched the first-ever clinical trials of engineered exosomes — nanometer-sized vesicles that shuttle messages between cells.
-
![Peter Altman, PhD, CEO at BioCardia]( "Inside BioCardia’s CardiAMP Cell Therapy")
Inside BioCardia’s CardiAMP Cell Therapy2/8/2021Peter Altman, PhD, CEO at BioCardia explains CardiAMP Heart Failure Trial and its best possible outcomes for patients.
